The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension
- 159 Downloads
Topiramate (TPM) has been reported to reduce body weight beyond a placebo in the treatment of obese participants, but the effect of this agent on components of energy balance has not yet been established in humans. Thus, the aim of this study was to study the impact of TPM on food preferences, measures of satiety, food intake, resting metabolic rate (RMR), and 24-h energy expenditure.
The study design consisted of a 6-month, single-center, randomized, double-blind, parallel group, placebo-controlled trial with a 6-month open-label extension. The study included 68 sedentary men with abdominal obesity (waist circumference ≥100 cm), of between 25 and 55 years of age, with a dyslipidemic profile and a body mass index (BMI) ≥27 and ≤40 kg/m2.
Treatment with TPM produced significant changes in anthropometric variables and body composition compared with placebo. However, at the end of the 1-year study, the placebo/TPM group showed similar weight loss and reduction in body fatness compared with the TPM/TPM group. For instance, at the end of the 12-month intervention, mean percentage of body weight loss from baseline was about −5% in both groups (−4 kg fat loss). Topiramate treatment reduced energy intake, be it in the context of an ad libitum buffet-type meal or under free living conditions. The 24-h daily energy expenditure (DEE) assessed by whole-body indirect calorimetry adjusted for body weight and age was not altered by TPM treatment.
Topiramate treatment produced significantly greater weight loss than placebo and the majority of this loss was explained by a decrease in body fat stores. Most of the weight loss effect produced by TPM therapy was observed within a period of 6 months. Finally, TPM treatment had an impact on energy balance through a reduction in food intake that appears to have created an energy deficit of about 30,000–40,000 kcal compared with treatment with the placebo over 6 months.
KeywordsAppetite Body composition Energy balance Food preferences Topiramate
- 8.Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M, for the OBES-002 Study Group (2004) A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 28:1399–1410PubMedCrossRefGoogle Scholar
- 10.Airlie (VA) Consensus Conference (1988) Standardization of anthropometric measurements. Human Kinetics Publishers, Champaign, ILGoogle Scholar
- 11.Lohman TG (1988) Anthropometry and body composition. In: Lohman TG, Roche AF, Martorell R (eds) Anthropometric standardization reference manual. Human Kinetics, Champaign, ILGoogle Scholar
- 12.Behnke AR, Wilmore JH (1974) Evaluation and regulation of body build and composition. In: Behnke AR (eds) Evaluation and regulation of body build and composition. Englewood Cliffs, Prentice-Hall, NJ, pp 20–37Google Scholar
- 15.Hill AJ, Blundell JE (1986) The effects of a high-protein or high-carbohydrate meal on subjective motivation to eat and food preferences. Nutr Behav 3:133–144Google Scholar
- 18.Canadian Nutrient File (2005) Health and Welfare, CanadaGoogle Scholar
- 21.Bouchard C (1985) Body-composition assessments in youth and adults. In: Roche E Jr (eds) Report of the Sixth ROSS Conference on Medical Research. Ross Laboratories, Colombus, OHGoogle Scholar
- 26.Prud’homme D, Dumont M, Brochu M, Alméras N, Nadeau A, Després JP (1997) Beneficial effects of a 12-week fenfluramine treatment on the cardiovascular disease risk profile of visceral obese men. Int J Obes 21[Suppl 2]:S-65Google Scholar